Medical News

RSS

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

Genzyme Corporation enters into asset purchase agreement with LabCorp

Genzyme Corporation today announced that it has entered into an asset purchase agreement under which Laboratory Corporation of America Holdings (LabCorp) will acquire Genzyme Genetics for $925 million in cash.

13 Sep 2010

Athersys signs agreement with RTI Biologics for MAPC technology access

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, and Athersys Inc. a leader in regenerative medicine and cell therapy research and development, announced today an agreement under which Athersys will provide RTI access to its Multipotent Adult Progenitor Cell (MAPC) technologies.

13 Sep 2010

JDRF selects Convio's Common Ground CRM for primary constituent relationship management

Convio, Inc. announced today that Juvenile Diabetes Research Foundation (JDRF) has selected Convio as their standard for constituent relationship management (CRM), online marketing and fundraising, and special events for JDRF's national headquarters and all chapters. JDRF will use Convio's integrated, on-demand marketing, fundraising and advocacy suite to power and support their efforts to engage constituents and raise money.

13 Sep 2010

LabCorp acquires Genzyme Genetics for $925 million

Laboratory Corporation of America Holdings, today announced that it has entered into a definitive agreement under which LabCorp will acquire Genzyme Genetics, a business unit of Genzyme Corp., in an all cash transaction valued at $925 million. Net of expected income tax benefits, less acquisition related expenses, the acquisition has a net cash cost to LabCorp of approximately $795 million.

13 Sep 2010

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

13 Sep 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.

13 Sep 2010

Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint

Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.

13 Sep 2010

Triclosan levels in treated biosolids

A study by U.S. Department of Agriculture (USDA) scientists and cooperators provides new details about how fertilizing soils with biosolids also introduces triclosan-an antibacterial agent in soaps and other cleaning supplies-into the environment.

13 Sep 2010

Scientists find low levels of bacteria in fields sprayed with swine manure

That swine manure sprayed on to fields adds valuable nutrients to the soil is well known. But what is not known is whether all that manure is bringing harmful bacteria with it.

13 Sep 2010

UIC Institute for Juvenile Research centennial anniversary celebrations on Oct. 1

The University of Illinois at Chicago College of Medicine's Institute for Juvenile Research will celebrate its centennial anniversary Oct. 1.

13 Sep 2010

New guidance on making complex decisions about injured athlete's return to play

When is it appropriate for an injured athlete to return to competition? A new three-step framework provides team physicians and other sport medicine clinicians with guidance on making complex decisions about return to play, reported in the September Clinical Journal of Sport Medicine.

13 Sep 2010

HR in Healthcare Forum takes place 17 - 20, October 2010 in Bahrain

HR professionals are challenged with developing robust and next generation recruitment, retention and engagement practices to meet the growing healthcare sector which is estimated to be valued between $15 billion and $18bn and is expected to grow five-fold by 2025.

From IQPC Ltd 13 Sep 2010

Less-invasive alternative to vasectomy

Pro-Vas® – the new faster, less-invasive alternative to traditional vasectomy – was featured Thursday in millions of homes and doctors' offices across the nation on "The Doctors" TV show. This nationally syndicated show highlights significant advancements in the world of health and medicine.

13 Sep 2010

Mental illness costs Canadian economy $51 billion in lost productivity

Mental illness is associated with more lost work days than any other chronic condition, costing the Canadian economy $51 billion annually in lost productivity. In the first study of its kind, researchers from the Centre for Addiction and Mental Health (CAMH) have calculated the actual cost of mental health leave and found that on average it's double the cost of a leave for a physical illness.

13 Sep 2010

Dr. Siegal & Son introduces CalciOs cookies to relieve heartburn

Dr. Siegal & Son, LLC, a new Vienna, Virginia based company launched by renowned physician and author Sanford Siegal, D.O., M.D., and his son, Matthew Siegal, the duo behind the internationally popular Dr. Siegal's COOKIE DIET brand, has introduced CalciOs cookies, a snack food that's enriched with calcium carbonate, a common source of dietary calcium supplementation that also neutralizes stomach acid and relieves occasional heartburn. U.S. and international patents are pending.

13 Sep 2010

Leukemia survivor to meet donor of bone marrow transplant

Ann Marie Del Fiacco, a 38-year-old Berwyn mother of two, owes her life to a stranger who volunteered to be a donor for her life-saving bone marrow transplant.

13 Sep 2010

RadNet reports definitive agreement to acquire Image Medical Corporation

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 191 fully owned and operated outpatient imaging centers, today reported it has executed a definitive agreement to acquire Image Medical Corporation, the parent of eRAD, Inc., for $10.75 million in a combination of cash and promissory notes.

13 Sep 2010

Non-invasive brain stimulation helps paralysed stroke patients regain motor function

Stroke patients who were left partially paralysed found that their condition improved after they received a simple and non-invasive method of brain stimulation, according to research in the September issue of the European Journal of Neurology.

13 Sep 2010

Researchers investigate human reovirus with chemotherapy for ovarian cancer

Researchers are now investigating whether the human reovirus, when prescribed along with chemotherapy, will provide a desperately needed "one-two punch" against ovarian cancer.

13 Sep 2010